Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | BUB1 | O43683 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | CDC25B | P30305 | 1/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CDC7 | O00311 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9026314 | 1.00 | LMNA (0.47) | LMNATSHRBCHEACHEAKT1 | |
| SCHEMBL8955111 | 1.00 | LMNA (0.47) | LMNATSHRBCHEACHEAKT1 | |
| SCHEMBL9026102 | 1.00 | LMNA (0.47) | LMNATSHRBCHEACHEAKT1 | |
| SCHEMBL9026109 | 1.00 | LMNA (0.47) | LMNATSHRBCHEACHEAKT1 | |
| SCHEMBL599775 | 0.82 | LMNA (0.46) | LMNATSHRBCHEACHEAKT1 | |
| SCHEMBL599776 | 0.82 | LMNA (0.46) | LMNATSHRBCHEACHEAKT1 | |
| SCHEMBL599240 | 0.82 | LMNA (0.46) | LMNATSHRBCHEACHEAKT1 | |
| SCHEMBL22110584 | 0.76 | TSHR (0.58) | LMNATSHRBCHEACHETAAR1 | |
| SCHEMBL2582669 | 0.76 | BCHE (0.56) | LMNATSHRBCHEACHEAKT1 | |
| SCHEMBL2580647 | 0.76 | BCHE (0.56) | LMNATSHRBCHEACHEAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220048912-A1 | CYCLOBUTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | JANSSEN PHARMACEUTICA NV (BE) | 2022-02-17 | — | — | US | disclosed |
| EP-3894394-A1 | CYCLOBUTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | Janssen BioPharma, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| WO-2020121122-A1 | CYCLOBUTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | Janssen Biopharma, Inc. (US) | 2020-06-18 | — | — | WO | disclosed |
| EP-0535448-B1 | Process and intermediates for the preparation of an antiviral agent containing a cyclobutyl group | SQUIBB & SONS INC (US) | 1996-06-26 | — | — | EP | disclosed |
| US-5525726-A | Process for the preparation of an antiviral agent | E. R. SQUIBB & SONS, INC. (US) | 1996-06-11 | — | — | US | disclosed |
| US-5516903-A | Process for preparing [IR-(1α,2β-3α)]-2-amino-9-[2,3-bis(hydroxymethyl)cyclobutyl]-1,9-dihydro-6H-purin-6-one | E. R. SQUIBB & SONS, INC. (US) | 1996-05-14 | — | — | US | disclosed |
| EP-0458363-B1 | Fluorinated bis(hydroxymethyl) cyclobutyl purines and pyrimidines | SQUIBB & SONS INC (US) | 1996-02-07 | — | — | EP | disclosed |
| US-5412134-A | Process for preparing diprotected 2,3-hydroxymethyl cyclobutanol | E. R. SQUIBB & SONS, INC. (US) | 1995-05-02 | — | — | US | disclosed |
| EP-0572209-A2 | Process for preparing diprotected 2,3-hydroxymethyl cyclobutanol | E.R. SQUIBB & SONS, INC. (US) | 1993-12-01 | — | — | EP | disclosed |
| US-5237095-A | Process for the preparation of an antiviral agent | E. R. SQUIBB & SONS, INC. (US) | 1993-08-17 | — | — | US | disclosed |
| US-5237096-A | Process for the preparation of an antiviral agent | E. R. SQUIBB & SONS, INC. (US) | 1993-08-17 | — | — | US | disclosed |
| US-5233086-A | Intermediates for the preparation of an antiviral agent | E. R. SQUIBB & SONS, INC. (US) | 1993-08-03 | — | — | US | disclosed |
| US-5218142-A | Process for the preparation of an antiviral agent | E. R. SQUIBB & SONS, INC. (US) | 1993-06-08 | — | — | US | disclosed |
| EP-0535448-A2 | Process and intermediates for the preparation of an antiviral agent containing a cyclobutyl group | E.R. SQUIBB & SONS, INC. (US) | 1993-04-07 | — | — | EP | disclosed |
| US-5185463-A | PROCESS FOR THE PREPARATION OF AN ANTIVIRAL AGENT | E. R. SQUIBB & SONS, INC. (US) | 1993-02-09 | — | — | US | disclosed |
| WO-1991018969-A1 | FLUORINATED BIS(HYDROXYMETHYL)CYCLOBUTYL PURINES AND PYRIMIDINES | E.R. SQUIBB & SONS, INC. (US) | 1991-12-12 | — | — | WO | disclosed |
| EP-0458363-A1 | Fluorinated bis(hydroxymethyl) cyclobutyl purines and pyrimidines | E.R. SQUIBB & SONS, INC. (US) | 1991-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048912-A1 | CYCLOBUTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | TYMP, POLB, HMBS | LMNA 1011/4885TSHR 4356/4885BCHE 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.